List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5728200/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood, 2007, 110, 2259-2267.	1.4	236
2	STAT3 in Cancer—Friend or Foe?. Cancers, 2014, 6, 1408-1440.	3.7	137
3	Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood, 2008, 112, 5171-5179.	1.4	82
4	Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors. International Journal of Pharmaceutics, 2008, 347, 118-127.	5.2	81
5	Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. Pharmaceutical Biology, 2017, 55, 729-739.	2.9	67
6	The PI3K/AKT/c-MYC Axis Promotes the Acquisition of Cancer Stem-Like Features in Esophageal Squamous Cell Carcinoma. Stem Cells, 2016, 34, 2040-2051.	3.2	63
7	The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years. Transplantation, 2018, 102, 1553-1562.	1.0	59
8	Flow Cytometric Detection of CD79a Expression in T-Cell Acute Lymphoblastic Leukemias. American Journal of Clinical Pathology, 2000, 113, 823-830.	0.7	49
9	Sinusoidal CD30-Positive Large B-Cell Lymphoma: A Morphologic Mimic of Anaplastic Large Cell Lymphoma. Modern Pathology, 2000, 13, 223-228.	5.5	49
10	Autotaxin is an inflammatory mediator and therapeutic target in thyroid cancer. Endocrine-Related Cancer, 2015, 22, 593-607.	3.1	48
11	The Opposing Function of STAT3 as an Oncoprotein and Tumor Suppressor Is Dictated by the Expression Status of STAT3β in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research, 2016, 22, 691-703.	7.0	46
12	CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets. Leukemia and Lymphoma, 1996, 20, 217-222.	1.3	42
13	Loss of miR-200b promotes invasion via activating the Kindlin-2/integrin β1/AKT pathway in esophageal squamous cell carcinoma: An E-cadherin-independent mechanism. Oncotarget, 2015, 6, 28949-28960.	1.8	41
14	The pathobiology of the oncogenic tyrosine kinase NPM-ALK: a brief update. Therapeutic Advances in Hematology, 2013, 4, 119-131.	2.5	36
15	The use of cellular thermal shift assay (CETSA) to study Crizotinib resistance in ALK-expressing human cancers. Scientific Reports, 2016, 6, 33710.	3.3	35
16	A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma. Journal of Hematology and Oncology, 2016, 9, 120.	17.0	34
17	Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma. Biomaterials, 2013, 34, 8718-8725.	11.4	33
18	Functional Plasticity of Gamma Delta T Cells and Breast Tumor Targets in Hypoxia. Frontiers in Immunology, 2018, 9, 1367.	4.8	30

#	Article	IF	CITATIONS
19	Methylation of <i>miR-155-3p</i> in mantle cell lymphoma and other non-Hodgkin's lymphomas. Oncotarget, 2014, 5, 9770-9782.	1.8	30
20	miR-200b induces cell cycle arrest and represses cell growth in esophageal squamous cell carcinoma. Carcinogenesis, 2016, 37, 858-869.	2.8	29
21	Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Modern Pathology, 2006, 19, 1498-1505.	5.5	28
22	PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer. EBioMedicine, 2016, 12, 86-97.	6.1	28
23	Oxidative stress induces the acquisition of cancer stem-like phenotype in breast cancer detectable by using a Sox2 regulatory region-2 (SRR2) reporter. Oncotarget, 2016, 7, 3111-3127.	1.8	27
24	Coexisting Thymic and Gastric Lymphomas of Mucosa-Associated Lymphoid Tissues in a Patient With Sjögren Syndrome. Archives of Pathology and Laboratory Medicine, 2000, 124, 770-773.	2.5	27
25	β-Catenin, a Sox2 binding partner, regulates the DNA binding and transcriptional activity of Sox2 in breast cancer cells. Cellular Signalling, 2014, 26, 492-501.	3.6	26
26	STAT3 but Not HIF-1α Is Important in Mediating Hypoxia-Induced Chemoresistance in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. Cancers, 2017, 9, 137.	3.7	26
27	Hypoxia Induces the Acquisition of Cancer Stem-like Phenotype Via Upregulation and Activation of Signal Transducer and Activator of Transcription-3 (STAT3) in MDA-MB-231, a Triple Negative Breast Cancer Cell Line. Cancer Microenvironment, 2018, 11, 141-152.	3.1	26
28	Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma. Cancers, 2019, 11, 248.	3.7	26
29	Correlation of STAT1 with Apoptosis and Cell-Cycle Markers in Esophageal Squamous Cell Carcinoma. PLoS ONE, 2014, 9, e113928.	2.5	25
30	Cyclin D1 Expression in Dysplastic Nevi. Archives of Pathology and Laboratory Medicine, 2001, 125, 208-210.	2.5	25
31	High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer. Oncotarget, 2017, 8, 28101-28115.	1.8	23
32	STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Blood, 2015, 126, 336-345.	1.4	22
33	YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells. BMC Cancer, 2014, 14, 328.	2.6	21
34	Triple negative breast cancers comprise a highly tumorigenic cell subpopulation detectable by its high responsiveness to a Sox2 regulatory region 2 (SRR2) reporter. Oncotarget, 2015, 6, 10366-10373.	1.8	20
35	Oxidative stress enhances tumorigenicity and stem-like features via the activation of the Wnt/l²-catenin/MYC/Sox2 axis in ALK-positive anaplastic large-cell lymphoma. BMC Cancer, 2018, 18, 361.	2.6	20
36	STAT1β enhances STAT1 function by protecting STAT1α from degradation in esophageal squamous cell carcinoma. Cell Death and Disease, 2017, 8, e3077-e3077.	6.3	19

#	Article	IF	CITATIONS
37	Glandular Malignant Peripheral Nerve Sheath Tumor. Archives of Pathology and Laboratory Medicine, 2000, 124, 1364-1368.	2.5	19
38	Biological and clinical significance of GSK-3beta in mantle cell lymphoma–an immunohistochemical study. International Journal of Clinical and Experimental Pathology, 2010, 3, 244-53.	0.5	19
39	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. Cancers, 2018, 10, 206.	3.7	16
40	Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma. Leukemia and Lymphoma, 2015, 57, 1-9.	1.3	15
41	Micellar nano-carriers for the delivery of STAT3 dimerization inhibitors to melanoma. Drug Delivery and Translational Research, 2017, 7, 571-581.	5.8	14
42	Postnatal changes of CD45 expression in peripheral blood T and B cells. British Journal of Haematology, 1994, 87, 251-257.	2.5	13
43	Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays. Breast Cancer Research, 2014, 16, 470.	5.0	13
44	Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. Journal of Biomedical Materials Research - Part A, 2013, 102, n/a-n/a.	4.0	13
45	Cytodiagnosis of metastatic amelanotic melanomas by fine-needle aspiration biopsy. , 1998, 84, 92-97.		11
46	High expression of β-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma. Scientific Reports, 2017, 7, 16863.	3.3	10
47	Phosphorylation of Sox2 at Threonine 116 is a Potential Marker to Identify a Subset of Breast Cancer Cells with High Tumorigenecity and Stem-Like Features. Cancers, 2018, 10, 41.	3.7	10
48	N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target. Breast Cancer Research and Treatment, 2021, 186, 79-87.	2.5	10
49	Elevated <i>ARG1</i> expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patients. Cancer Biology and Therapy, 2015, 16, 1281-1288.	3.4	9
50	Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent. Cancers, 2021, 13, 181.	3.7	9
51	Expression of Nucleoside Transporters and Deoxycytidine Kinase Proteins in Muscle Invasive Urothelial Carcinoma of the Bladder: Correlation with Pathological Response to Neoadjuvant Platinum/Gemcitabine Combination Chemotherapy. Journal of Urology, 2014, 191, 35-39.	0.4	6
52	NPM-ALK Is a Key Regulator of the Oncoprotein FOXM1 in ALK-Positive Anaplastic Large Cell Lymphoma. Cancers, 2019, 11, 1119.	3.7	6
53	Silibinin induces immunogenic cell death in cancer cells and enhances the induced immunogenicity by chemotherapy. BioImpacts, 2023, 13, 51-61.	1.5	6
54	Development of Traceable Rituximab-Modified PEO-Polyester Micelles by Postinsertion of PEG-phospholipids for Targeting of B-cell Lymphoma. ACS Omega, 2019, 4, 18867-18879.	3.5	5

#	Article	IF	CITATIONS
55	Identification and Characterization of Cancer Stem-Like Cells in ALK-Positive Anaplastic Large Cell Lymphoma Using the SORE6 Reporter. Current Issues in Molecular Biology, 2021, 43, 543-557.	2.4	5
56	The Dual Role of Autophagy in Crizotinib-Treated ALK+ ALCL: From the Lymphoma Cells Drug Resistance to Their Demise. Cells, 2021, 10, 2517.	4.1	5
57	Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma Blood, 2005, 106, 2407-2407.	1.4	5
58	Determining the Mechanism of Transformation of Follicular Lymphoma into Diffuse Large B Cell Lymphoma Blood, 2007, 110, 181-181.	1.4	5
59	New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 54-63.	1.2	4
60	Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands. BioImpacts, 2022, , .	1.5	4
61	Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism. Current Issues in Molecular Biology, 2021, 43, 313-323.	2.4	3
62	Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Archives of Pathology and Laboratory Medicine, 2021, , .	2.5	3
63	Bortezomib Induces an Antioxidant and ER-Stress Response Gene Expression Signature in Mantle Cell Lymphoma: Implications for Response Prediction and Optimized Chemotherapy Regimens Blood, 2006, 108, 830-830.	1.4	3
64	BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL. Cancers, 2022, 14, 151.	3.7	2
65	Nodular lymphocyte predominant Hodgkin's lymphoma of the cervix: A case report of a rare entity. Gynecologic Oncology Case Reports, 2013, 4, 4-6.	0.9	1
66	Gene Methylation and Silencing of WIF1 Is a Frequent Genetic Abnormality in Mantle Cell Lymphoma. International Journal of Molecular Sciences, 2021, 22, 893.	4.1	1
67	Epidemiology of Post-Transplant Lymphoproliferative Disorders in Children with Solid Organ Transplant over 34 Years of a Single Center Experience. Blood, 2019, 134, 1602-1602.	1.4	1
68	Role of Jak3 in Chronic Myeloid Leukemia: Evidence To Identify Jak3 as a Potential Therapeutic Target Blood, 2005, 106, 2870-2870.	1.4	1
69	Gene Expression Profiling of Mycosis Fungoides in Early and Tumor Stage—A Proof-of-Concept Study Using Laser Capture/Single Cell Microdissection and NanoString Analysis. Cells, 2021, 10, 3190.	4.1	1
70	Bortezomib Activity Against Mantle Cell Lymphoma Overcomes Classic Mechanisms of Drug Resistance and Targets Cell Cycle Control Blood, 2006, 108, 4393-4393.	1.4	0
71	Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Tranplantation $\hat{a} \in$ Evidence to Support the Existence of a Lymphoma Progenitor Cell Blood, 2006, 108, 2415-2415.	1.4	0
72	Epigenetic Regulation of the WNT Canonical Pathway in Mantle Cell Lymphoma Blood, 2008, 112, 3340-3340.	1.4	0

#	Article	IF	CITATIONS
73	Morphologic Evolution in Post-Transplant Lymphoproliferative Disorders (PTLD): A Clinicopathologic Case Series. Blood, 2015, 126, 5008-5008.	1.4	0
74	CD3 T-Cell Infiltrates at Diagnosis Predicts Overall Survival in Solid Organ Transplant Recipients with Post-Transplant Lymphoproliferative Disorders (PTLD). Blood, 2016, 128, 1873-1873.	1.4	0
75	The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients. Oncotarget, 2018, 9, 10698-10713.	1.8	0
76	FOXM1 and the NPM-ALK/STAT3 Axis Form a Novel Positive Feedback Loop in Promoting the Oncogenesis of ALK-Positive Anaplastic Large Cell Lymphoma. Blood, 2018, 132, 3921-3921.	1.4	0